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Abstract
The role of androgen receptor (AR) mutations in androgen-indepen-
dent prostate cancer (PCa) was determined by examining AR transcripts
and genes from a large series of bone marrow metastases. Mutations were
found in 5 of 16 patients who received combined androgen blockade with
the AR antagonist flutamide, and these mutant ARs were strongly stim-
ulated by flutamide. In contrast, the single mutant AR found among 17
patients treated with androgen ablation monotherapy was not flutamide
stimulated. Patients with flutamide-stimulated AR mutations responded
to subsequent treatment with bicalutamide, an AR antagonist that blocks
the mutant ARs. These findings demonstrate that AR mutations occur in
response to strong selective pressure from flutamide treatment.
Introduction
PCa3 is dependent upon androgen stimulation mediated by the AR,
a member of the steroid hormone receptor family of ligand-dependent
nuclear receptors. The primary treatment for metastatic PCa is re-
moval of testicular androgens, carried out most often by surgical or
medical castration (androgen ablation monotherapy). Many patients
are also treated with an AR antagonist (antiandrogen) to block the
effects of androgens produced by the adrenal glands (commonly
referred to as combined androgen blockade). Although most patients
initially respond, all eventually relapse with tumors that are clinically
androgen independent (1). The mechanisms through which these
tumors develop androgen independence are not known and may be
diverse. Mutations in the AR and amplification of the AR gene have
been identified in some androgen-independent prostate cancers (2–7),
but how and to what extent these changes contribute to the develop-
ment of androgen-independent PCa remain unclear. This study deter-
mined the role of AR mutations in androgen-independent PCa through
an analysis of metastatic androgen-independent prostate cancers in
bone marrow biopsies from a large series of patients.
Materials and Methods
Tissue Acquisition. After informed consent, a bone marrow biopsy was
obtained from the posterior iliac crest in patients with androgen-independent
PCa, as described previously (5). Frozen sections were then analyzed histo-
logically for tumor. PCa was identified in the bone marrow biopsies from
;40% of the patients biopsied, and these samples form the basis of this
analysis.
RT-PCR Analysis of AR Transcripts. RNA was extracted from approx-
imately five adjacent frozen sections of 6 mm using RNazol-B (TM Cinna
Scientific, Friendswood, TX), and cDNA was synthesized with MMTV reverse
transcriptase and an AR antisense primer located in the 39 UTR (GCAAATA-
GAATTCAGGAACA). PCR amplifications were carried out with Taq DNA
polymerase, a sense primer in the ligand binding domain (ACTCCTTTG-
CAGCCTTGC), and an internal antisense primer in the 39 UTR (ACAGACT-
GTACATCAATAGAGGAAATTC) for 25 cycles. Secondary PCR amplifica-
tions were carried out for 25 cycles with nested 59 (GCTCTAGACTCAATGA-
ACTGGGAGAGAGAC) and 39 UTR (GGCACTGCAGAGGAGTAGTGC-
AGA) primers, the former introducing an XbaI site. Negative control samples
in which the reverse transcriptase step was omitted were included in all
amplifications and did not amplify. The PCR products were cloned, and at least
five colonies were sequenced. The region sequenced in all clones was from
codon 701 through the stop codon. For direct sequencing of uncloned PCR
products, the products were purified using a Microcon-100 membrane (Ami-
con, Beverly, MA).
Genomic DNA Sequencing. DNA was extracted from four to five adjacent
frozen sections by overnight proteinase K digestion, followed by phenol/
chloroform extraction. The DNA was PCR amplified using a primer in intron
7 (GAGGCCACCTCCTTGTCAACCCTG) and primers in the 39 UTR of exon
8. The PCR products were purified and directly sequenced as above.
Transient Transfections. CV-1 cells in 24-well plates were transfected
using Lipofectamine according to the manufacturer’s directions (Life Tech-
nologies, Inc.). The wild-type AR expression vector, pSV.ARo, was kindly
provided by Dr. A. Brinkmann (Erasmus University, Rotterdam, the Nether-
lands), and mutant ARs were constructed from this as described (5). The
reported plasmid, pMMTVpLuc, was provided by Dr. Richard Pestell (Albert
Einstein, New York, NY) and was also described previously (5). Each trans-
fection was normalized for b-galactosidase activity from the cotransfected
plasmid pSVgal (Promega Corp., Madison, WI). Each well received 20 ng of
AR expression vector, 200 ng of pMMTVLuc, and 50 ng of pSVgal. Trans-
fected cells were assayed after 24 h in medium containing charcoal/dextran-
stripped FCS (Hyclone, Logan, UT) and the indicated hormone or AR antag-
onist. All samples were done in quadruplicate, and data shown are
representative of at least three experiments.
Results
AR Mutations Detected by RT-PCR. Bone marrow is the most
frequent site of metastatic PCa and can provide a source of tumor cells
uncontaminated with benign prostatic tissue, which also expresses the
AR. It was shown previously that the AR gene, which is on the X
chromosome, was expressed at very low or undetectable levels in
bone marrow biopsies that did not contain histological evidence of
tumor (5). Therefore, RT-PCR was used to amplify the ligand binding
domain of AR transcripts derived from tumor cells in histologically
PCa-positive biopsies. The PCR products were cloned, and multiple
clones (at least five per biopsy) were analyzed by DNA sequencing.
All mutations were confirmed by repeating the PCR amplification,
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cloning, and sequencing of AR transcripts from another aliquot of
cDNA.
In the group of 17 evaluable patients treated initially by androgen
ablation without an AR antagonist, a single patient with a point
mutation was identified (patient 51, aspartate to asparagine in codon
890; Table 1). As shown by direct sequencing of AR PCR products,
this mutation was present in the majority of AR transcripts (Fig. 1A).
Analysis of genomic DNA from peripheral blood lymphocytes con-
firmed that the D890N change in this patient was a mutation and not
a polymorphism (data not shown).
In contrast, AR mutations were detected in 5 of the 16 evaluable
patients who received combined androgen blockade with the AR
antagonist flutamide (Table 1). In all five cases, a mutation in codon
877, ACT (threonine) to GCT (alanine; T877A) was found. In four of
these patients, the T877A was the only mutant AR isolated and was
found in most or all of the clones sequenced. A second codon 877
mutation, ACT (threonine) to AGT (serine), was identified in one
patient (Table 1, patient 14) and represented the majority of clones
isolated from this patient. Direct sequencing of uncloned PCR-ampli-
fied AR transcripts from patients 2, 6, 12, and 55 confirmed that the
T877A mutant represented most of the AR transcripts (Fig. 1A).
Direct sequencing similarly confirmed that the T877S mutant was the
major transcript in patient 14.
AR Mutations Detected by Analysis of Genomic DNA. In four
of the patients with mutant ARs, the initial frozen sections contained
predominantly tumor (not shown). Therefore, genomic DNA from
these biopsies could be readily analyzed to further confirm the RT-
PCR-based results and to determine whether the AR mutations were
in a large fraction of the tumor cells versus a small fraction expressing
high levels of AR message. Further frozen sections were cut from the
appropriate blocks and again analyzed histologically, confirming that
the sections were largely replaced by tumor (Fig. 1B). DNA was then
extracted from adjacent frozen sections, and a portion of exon 8,
containing codons 877 and 890, was amplified with a 59 primer in
intron 7 and 39 exon primers and directly sequenced.
The D890N mutation was clearly observed in the DNA from patient
51 (Fig. 1C), demonstrating that this mutation was present in most or
all of the tumor cells. The sequence analysis of genomic DNA from
patients 6 and 12 similarly demonstrated that most or all of the tumor
cells from these biopsies had the T877A mutant AR (Fig. 1C). In
patient 14, only a minority of the PCR-amplified genomic DNA had
the T877S mutation (AGT to ACT on the antisense strand in Fig. 1C).
A larger fraction had the T877A mutation (AGT to AGC on the
antisense strand), indicating that tumor cells with the former mutation
expressed higher levels of AR transcripts.
Functional Analysis of Mutant ARs. Mutations in codon 877
were identified previously in advanced PCa from patients (3–6) and in
a PCa cell line, LNCaP (8). Importantly, functional studies have
shown that both the T877A and T877S mutations alter the AR so that
hydroxyflutamide, the active metabolite of the AR antagonist flut-
amide, becomes a strong agonist (8–10). Therefore, identification
here of these codon 877 mutations in patients who were treated with
flutamide suggested that AR mutations resulting in activation by
flutamide were positively selected by the drug. The D890N mutation
Table 1 Androgen receptors in androgen-independent PCa patients
Primary treatmenta Response (mo)
Flutamide withdrawal
response AR
PSA decline in response
to bicalutamide
1 LHRH 15 wt None
2 LHRH1F 20 None Codon 877 ACT(Thr)3GCT(Ala) 86%b
4 ORCH1F 36 None wt 10%
5 LHRH1F 12 None wt 25%
6 LHRH1F 24 None Codon 877 ACT(Thr)3GCT(Ala) 30%
9 LHRHc 24 wt None
12 LHRH1F 24 12 mo Codon 877 ACT(Thr)3GCT(Ala) .99%d
13 LHRH1F 48 None wt None
14 LHRH1F 20 None Codon 877 ACT(Thr)3AGT(Ser) 51%
Codon 877 ACT(Thr)3GCT(Ala)
16 ORCHc 12 wt None
19 ORCH 18 No amplification
20 LHRH1F 2 None wt None
22 LHRH 42 No amplification
24 ORCH 12 No amplification
41 ORCHe 17 wt
42 ORCH1F 9 None No amplification
43 DESf 72 No amplification
44 ORCH 14 wt
45 ORCH NA wt
46 ORCHg 19 wt
47 LHRHc 20 wt
48 LHRH1F 20 None wt
49 LHRH 15 wt
50 LHRH 24 No amplification
51 LHRH 12 Codon 890 GAC(Asp)3AAC(Asn) None
52 LHRH 18 wt None
53 LHRH1F 6 NAh wt
54 LHRH 38 wt
55 LHRH1F 32 NA Codon 877 ACT(Thr)3GCT(Ala)
57 LHRH1F 3 NA wt
59 LHRH1F 13 NA wt
60 LHRH1F 12 NA wt
63 LHRH1F 33 NA wt
a Treatments were LHRH agonist (LHRH), orchiectomy (ORCH), LHRH agonist plus flutamide (LHRH1F), or diethylstilbestrol (DES). wt, wild type.
b Reflects PSA decline after 4 months of therapy, at which time bicalutamide was discontinued because of a possible drug interaction.
c No response to subsequent flutamide treatment.
d PSA fell to undetectable during therapy.
e Fifteen-month response to subsequent flutamide; no flutamide withdrawal response.
f Thirty-month response to subsequent orchiectomy plus flutamide; positive flutamide withdrawal response.
g Twelve-month response to subsequent flutamide; no flutamide withdrawal response.
h Data on these patients’ responses were not available.
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was found in a patient who was not treated with flutamide. This
mutant AR was analyzed functionally for its response to hydroxyflu-
tamide in comparison with the wild-type and T877A mutant ARs.
CV-1 cells were transiently transfected with wild-type or mutant
AR expression vectors and a luciferase reporter gene regulated by the
androgen-responsive elements in the MMTV-LTR, pMMTVLuc (5,
10). The wild-type and mutant ARs showed minimal activity in
steroid hormone-free medium but were strongly stimulated (;100-
fold induction) by DHT (Fig. 2). As shown previously, the T877A
(Fig. 2) and T877S (not shown) mutant ARs were strongly stimulated
by hydroxyflutamide at concentrations ,100 nM (10). This is likely
significant in vivo because the serum concentrations achieved in
patients are in the micromolar range (11). In contrast, the D890N AR
was only weakly stimulated at the highest hydroxyflutamide concen-
tration. Therefore, although the functional significance of the D890N
mutation is not clear, the results support the conclusion that flutamide
treatment selects for AR mutations that are strongly activated by
hydroxyflutamide.
Clinical Responses to Secondary Hormonal Therapies. Some
patients treated by androgen ablation in conjunction with flutamide
who subsequently develop androgen-independent PCa respond to
discontinuation of their flutamide, a phenomena termed the flutamide
withdrawal response (12, 13). Although flutamide-activated mutant
ARs would be expected to result in flutamide withdrawal responses,
this response was seen in only one of the five patients with a codon
877 mutation (patient 12, Table 1). An explanation for the lack of a
flutamide withdrawal response in these patients is that these mutant
ARs would have had ongoing activation by other steroid hormones,
particularly those produced by the adrenals, when flutamide treatment
was discontinued (10). Indeed, suppression of adrenal steroid hor-
mone synthesis with aminoglutethimide has been reported to increase
the response to flutamide withdrawal (14–16).
Both the T877A and T877S mutant ARs are inhibited by bicalu-
tamide, a related nonsteroidal AR antagonist approved recently for
prostate cancer treatment (10). Therefore, responses to this drug
should be demonstrable in vivo in prostate cancer patients with
these mutant ARs if they contribute significantly to the disease.
Some of the patients studied here were enrolled in a clinical trial
of high-dose bicalutamide (150 mg/day) immediately after bone
marrow biopsy (17). Each of the patients with codon 877 mutations
Fig. 1. Direct sequencing of PCR-amplified AR transcripts and genes. A, direct sequencing of RT-PCR products. The region containing the mutation is shown from the positive
strand for patient 51 and negative strand for the remaining patients. The wild-type sequence is shown below each panel, and the amino acid encoded by the mutant AR is shown above.
B, representative regions of sections used for DNA extraction from the indicated patients. C, direct sequencing of extracted and amplified genomic DNA. The negative strand sequence
is shown for each, and the wild-type sequences for codons 890 (patient 51) and 877 (patients 6, 12, and 14) are shown.
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enrolled had responses to the bicalutamide treatment, with their
serum PSA levels declining by between 30% and . 99% (Table 1).
These results indicated that ARs inhibited by bicalutamide, but not
flutamide, contributed to tumor progression in these patients. The
variability in responses to bicalutamide likely reflects tumor cell
heterogeneity in these patients with advanced disease, which
would clearly limit the clinical effects from this and other thera-
pies.
Clinical data from this and another bicalutamide trial (17, 18)
showed a significant correlation between PSA responses, clinical
responses, and previous flutamide treatment. It is not clear whether
this reflects AR mutations in all cases, because responses to
bicalutamide were seen in some flutamide-treated patients with
wild-type ARs (Table 1, patients 4 and 5). Because the AR analysis
in all patients was based upon a biopsy from a single site, tumor
cells at other sites with AR mutations could have contributed to
bicalutamide responses in some patients. Alternatively, because
hydroxyflutamide, but not bicalutamide, is a weak agonist of the
wild-type AR (10), mechanisms other that AR mutation may
contribute to bicalutamide responses in patients treated previously
with flutamide.
Discussion
These findings provide direct evidence that AR mutations occur in
response to selective pressure from AR antagonist treatment and that
these mutations contribute to PCa progression after androgen ablation
therapy. Most significantly, the selection for rare tumor cells with
hydroxyflutamide-stimulated mutant ARs indicates that ongoing AR
activity is critical for tumor cell survival after androgen ablation and
that mutation of the AR is an important mechanism for achieving this
activity in flutamide-treated patients. In contrast, AR mutation ap-
pears to be a less important mechanism for maintaining AR stimula-
tion in patients treated with androgen ablation monotherapy, perhaps
due to the ability of residual adrenal androgens to provide an adequate
level of stimulation through the wild-type AR. Although the use of an
AR antagonist appears to significantly alter the mechanisms used by
tumor cells to escape from androgen ablation therapy, results from a
series of clinical trials comparing androgen ablation monotherapy to
combination therapy with flutamide or other AR antagonists have not
shown substantial increases in progression-free or overall survival in
the combination therapy groups, except perhaps in patients with
low-volume disease (19, 20).
The hydroxyflutamide-activated mutant ARs identified here
were all altered in codon 877. In a previous study, we identified
two additional flutamide-treated patients with hydroxyflutamide-
activated ARs, one with a codon 877 mutation (T877S) and one
with a codon 874 mutation (H874Y; Refs. 5 and 10). The finding
of particular codon 877 mutations in these and other studies (4, 6)
suggests that this functional change can be mediated by only a very
limited number of structural changes in the AR. It should also be
noted that codon 874 and 877 mutations may provide selective
advantages in addition to altering flutamide responses, because
both have been identified in cell lines derived from patients not
treated with flutamide (CWR22 and LNCaP cells, respectively;
Refs. 8 and 21). A more weakly hydroxyflutamide-activated mu-
tant AR (V715M) was also identified previously in a patient treated
with flutamide (2, 10).
These results have several significant implications for the hormonal
therapy of PCa: (a) the selection for rare tumor cells with mutant ARs
indicates that AR antagonists may improve responses to androgen
ablation therapy initially but subsequently accelerate the growth of
surviving tumor cells; (b) alternative methods to further block the
AR-mediated signaling that appears critical for tumor cell survival,
such as targeting AR-associated coactivator proteins, downstream
target genes, or signal transduction pathways that interact with the
AR, may enhance responses to androgen ablation monotherapy or
combined androgen blockade; and (c) the additive or synergistic
effects of cytotoxic chemotherapy used early in conjunction with
androgen ablation therapy may be very effective if, as this study
suggests, only a relatively small number of tumor cells survive com-
bined androgen blockade.
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